Entasis Therapeutics Holdings Inc.
ETTXDelisted Jul 11, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724344
Entasis Therapeutics Holdings Inc. was delisted on Jul 11, 2022; its insiders filed their last Form 4 on Jul 13, 2022; 27 institutions reported holding it in 13F filings for Q2 2022, worth $12.5M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 27
- Q2 2022, +5 vs. previous quarter
- 13F value
- $12.5M
- Reported value at the end of Q2 2022
- Superinvestors holding
- 0
- At the end of Q2 2022
Superinvestors holding ETTX, Q2 2022
No superinvestor reported holding ETTX at the end of Q2 2022.
Latest insider trades
Open-market purchases and sales by Entasis Therapeutics Holdings Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 13, 2022 (view filing)9:27 PM ET | Jul 8-11 | 5 daysLate | Innoviva, Inc. and 1 other10% Owner | PPurchase | +19.3M | $2.20 | +$42.4M | +192.7%29.3M after | 2 lots |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Perros ManoussosSee Remarks | SSale | −12.0K | $3.19 | −$38.2K | −7.5%147.5K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Mueller John PatrickChief Development Officer | SSale | −4.00K | $3.19 | −$12.8K | −8.0%46.0K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Gutch MichaelSee Remarks | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Tommasi RubenChief Scientific Officer | SSale | −3.76K | $3.19 | −$12.0K | −5.2%68.3K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Keiley Elizabeth MGeneral Counsel | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Altarac DavidChief Medical Officer | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after | |
| Oct 20, 2021 (view filing) | Oct 19 | 1 day | Ronsheim MatthewSee Remarks | SSale | −3.76K | $3.19 | −$12.0K | −7.5%46.2K after |
Top 10 13F holders, Q2 2022
The largest institutional positions in Entasis Therapeutics Holdings Inc. at the end of Q2 2022; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gardner Lewis Asset Management L P | 1,249,778 | $2.75M | 0.58% | +1,249,778 | New |
| Beryl Capital Management LLC | 1,131,772 | $2.49M | 0.26% | +1,131,772 | New |
| TPG GP A, LLC | 1,020,748 | $2.25M | 0.03% | 00.0% | Unchanged |
| Vanguard Group Inc | 502,622 | $1.11M | 0.00% | +18,899+3.9% | Added |
| Susquehanna International Group, LLP | 393,563 | $866.0K | 0.00% | +376,187+2,165.0% | Added |
| Renaissance Technologies LLC | 350,345 | $771.0K | 0.00% | +26,500+8.2% | Added |
| Geode Capital Management, LLC | 180,827 | $397.0K | 0.00% | +44,970+33.1% | Added |
| Deltec Asset Management LLC | 155,614 | $342.0K | 0.08% | +155,614 | New |
| Ergoteles LLC | 135,323 | $298.0K | 0.01% | +135,323 | New |
| Bridgeway Capital Management, LLC | 132,600 | $292.0K | 0.01% | 00.0% | Unchanged |